Aesculap, Inc. Acquires Dextera Surgical Inc.

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

February 21, 2018:

Aesculap announced they have acquired Dextera Surgical, Inc.

Aesculap notes Dextera designs, manufactures and markets proprietary medical devices for surgical procedures, including surgical staplers and innovative devices for coronary artery bypass graft (CABG) surgery.

Aesculap will oversee operations in Redwood City, CA to continue the manufacturing and distribution of Dextera’s products.

Through the acquisition, Aesculap expands its portfolio of premium solutions for beating heart coronary and video-assisted thoracic surgery. The innovative MicroCutter 5/80 stapler, PAS-Port® proximal anastomosis system, C-Port® distal anastomosis system and technology portfolio supports Aesculap’s growth in the cardio-thoracic surgery market.

spot_img

DON'T MISS

Related Articles